Tilray Brands, Inc. (TLRY) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $6.91. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 1 out of 7 criteria passed.
Analyst consensus target is TLRY = $10 (+44.7% upside).
Valuation: TLRY trades at a trailing Price-to-Earnings (P/E) of -0.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.01.
Financials: revenue is $1.1B, +22.8%/yr average growth. Net income is $3.0B (loss), growing at -424.7%/yr. Net profit margin is -266.3% (negative). Gross margin is 29.3% (+10.7 pp trend).
Balance sheet: total debt is $451M against $2.1B equity (Debt-to-Equity (D/E) ratio 0.22, conservative). Current ratio is 2.46 (strong liquidity). Debt-to-assets is 15.5%. Total assets: $2.9B.
Analyst outlook: 5 / 20 analysts rate TLRY as buy (25%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 96/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 47/100 (Partial), Future 52/100 (Partial), Income 10/100 (Fail).
